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Abstract
Background: The effect of highly active antiretroviral therapy (HAART) on the survival of HIV-infected children has not been
well quantified. Because most pediatric HIV occurs in low- and middle-income countries, our objective was to provide a first
estimate of this effect among children living in a resource-deprived setting.
Methods and Findings: Observational data from HAART-naı¨ve children enrolled into an HIV care and treatment program in
Kinshasa, Democratic Republic of the Congo, between December 2004 and May 2010 were analyzed. We used marginal
structural models to estimate the effect of HAART on survival while accounting for time-dependent confounders affected by
exposure. At the start of follow-up, the median age of the 790 children was 5.9 y, 528 (66.8%) had advanced or severe
immunodeficiency, and 405 (51.3%) were in HIV clinical stage 3 or 4. The children were observed for a median of 31.2 mo
and contributed a total of 2,089.8 person-years. Eighty children (10.1%) died, 619 (78.4%) initiated HAART, six (0.8%)
transferred to a different care provider, and 76 (9.6%) were lost to follow-up. The mortality rate was 3.2 deaths per 100
person-years (95% confidence interval [CI] 2.4–4.2) during receipt of HAART and 6.0 deaths per 100 person-years (95% CI
4.1–8.6) during receipt of primary HIV care only. The mortality hazard ratio comparing HAART with no HAART from a
marginal structural model was 0.25 (95% CI 0.06–0.95).
Conclusions: HAART reduced the hazard of mortality in HIV-infected children in Kinshasa by 75%, an estimate that is similar
in magnitude but with lower precision than the reported effect of HAART on survival among children in the United States.
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Introduction
Highly active antiretroviral therapy (HAART) clearly improves the
survival of adults living with HIV [1,2], even when initiated at higher
CD4 cell counts [3,4], but less is known about the degree to which
HAART affects the survival of HIV-infected children. The course of
HIV disease in children, in part because of deleterious impacts of the
virus on the immature thymus [5], leading to high HIV RNA viremia
[6] and rapid death [7], is distinct from that in adults [8]. Response to
antiretroviral treatment also differs across age groups [9]. Given that
the natural history of HIV and response to therapy vary by age and
that more than two million children worldwide are living with HIV
[10], the extrapolation of results from studies of adults to pediatric
populations is not appropriate. It is imperative that the effect of
HAART on survival is specifically quantified in children.
Most observational studies on the effects of treatment on
survival in children have not used the epidemiological methods
necessary to account for potential biases inherent to their design,
including confounding by indication. One study not employing
methods necessary to account for such possible biases found that
HAART, relative to no therapy, decreased the mortality rate by
71% among 1,142 Italian children [11]. A recent study of 1,236
children in the United States [12], which used optimal analytical
methods, observed a result similar to that of the Italian study.
More than 90% of children receiving HAART live in low-
resource areas [10,13]. Because multiple factors that may
adversely affect treatment outcomes including delayed presenta-
tion to care and a higher incidence of co-occurring infectious and
non-infectious conditions such as undernutrition are more
common in such environments [14], there is a specific need for
information on the effects of HAART on patients living in these
areas. Studies in adults have revealed higher mortality after
HAART initiation in resource-poor settings than in resource-
privileged settings after adjusting for age, CD4 cell count, and
disease stage [15,16]. Although investigations in pediatric cohorts
from Zambia [17], Haiti [18], and Coˆte d’Ivoire [19] have shown
that treatment improves immunological, hematological, and
growth outcomes, and results in mortality rates lower than those
observed in the pre-antiretroviral era [7], an estimate of the effect
on mortality of HAART, compared to no HAART, has never
been accurately quantified among children in a resource-deprived
setting. This is true of two recent multi-site studies in sub-Saharan
Africa [20,21], as well as studies in Thailand [22], Zambia [23],
Coˆte d’Ivoire [24], and Lesotho [25] that have provided valuable
information on mortality among children receiving HAART,
including rates during the early and late therapeutic periods.
In this study, we investigated the effect of HAART on mortality
in an observational clinical cohort of HIV-infected children in the
Democratic Republic of the Congo (DRC). As HAART is
typically initiated in sicker patients, for example, those with lower
CD4 cell counts, it is necessary to adjust for this confounding by
indication to estimate its effect on survival. But adjusting for a
time-dependent factor such as CD4 cell count that is itself affected
by prior HAART exposure can yield a measure not interpretable
as the total effect of HAART, because the effects of therapy are
mediated in part through modulation of CD4 count. We therefore
used a method that adjusts for time-dependent confounding by
indication while accounting for confounders affected by prior
exposure: marginal structural models.
Methods
Ethics Statement
Parental informed consent for the HIV care program, in
addition to assent from minors 12 y of age or older, was obtained
for all participants. All research was conducted according to the
principles expressed in the Declaration of Helsinki and was
approved by the Ethics Committee of the Kinshasa School of
Public Health (approvals ESP/CE/010 and ESP/CE/014) and
the University of North Carolina at Chapel Hill Institutional
Review Board (studies 04-1007, 05-2311, and 10-0661).
Study Population, Measurements, and Follow-up
The source of information for this study was a comprehensive
HIV care and treatment program serving children and family
members at Kalembe Lembe Pediatric Hospital and Bomoi
Healthcare Center in Kinshasa, DRC [26]. HIV infection was
confirmed by serological testing, with HIV viral load or DNA
PCR used in infants under 18 mo of age. Patients were managed
in accordance with World Health Organization (WHO) [27,28]
and national [29] guidelines regarding diagnosis and treatment of
opportunistic infections, laboratory monitoring, and provision of
cotrimoxazole and HAART when clinically or immunologically
indicated. HAART could be initiated as soon as 1 wk following
enrollment or at any visit thereafter, with the standard first-line
regimen comprising zidovudine or stavudine, lamivudine, and
nevirapine (NVP) or efavirenz. Prior to October 2009, zidovudine,
lamivudine, and NVP were given as syrups and dosed according to
milligrams per kilogram or body surface area, as appropriate, per
package inserts. From October 2009 on, pediatric fixed-dose
combination tablets were administered based on WHO-recom-
mended weight-banded dosing. Because virological diagnostics
were occasionally unavailable, enrolled infants under 2 y of age
did not always begin treatment immediately as recommended by
WHO [28]. Visits were scheduled monthly for patients receiving
HAART and quarterly for those not receiving HAART, with
additional unscheduled visits made by individuals needing acute
care. Clinical data, documented by physicians during patient visits
using standardized forms, were collected. CD4 cell count and
percentage were evaluated every 6 mo at the DRC National AIDS
Reference Laboratory, but viral load was not routinely assessed
because of infrequent availability of the assay.
The population for this analysis was HIV-infected children who
were naı¨ve to antiretroviral therapy and under 18 y of age at the
start of follow-up. The beginning of follow-up, also referred to as
baseline, was the initiation of HIV care (between December 2004
and May 2010) unless a child’s CD4 percentage was not obtained
at that visit, in which case baseline was defined as the date of the
first available CD4 percentage result. Consistent with precedent
[12,30], allowing follow-up to start at first CD4 percentage meant
that children did not have to be excluded due to missing
immunological data. Follow-up ended at death or at the last
clinic visit prior to transfer to a different care provider, loss to
follow-up, or 1 August 2010. If children withdrew from care or
could not be located by three tracking attempts after a missed visit,
they were classified as lost to follow-up. Children contributed non-
HAART person-time until they initiated HAART. Program
personnel gathered information on children who died, including
the date and suspected cause of death.
Statistical Analysis
Mortality rates were expressed as deaths per 100 person-years,
with rates and rate ratios calculated via Poisson regression. To
compare proportions, we used the chi-square or mean score test,
while medians were compared by the Mann-Whitney test. SAS
version 9.2 (SAS Institute) was used for all analyses.
To estimate the total effect of HAART on mortality, one must
adjust for confounders measured at baseline as well as time-varying
confounders affected by prior exposure, factors that are causal
HAART Improves Pediatric Survival in DRC
PLoS Medicine | www.plosmedicine.org 2 June 2011 | Volume 8 | Issue 6 | e1001044
intermediates between treatment and death while simultaneously
common causes of subsequent treatment and death [31]. We did so
by fitting four logistic regression models to predict subject- and time-
specific probabilities of treatment and censoring as a function of
covariate histories, and using these predicted probabilities to
construct stabilized inverse probability of treatment and censoring
(IPTC) weights. The model for the denominator of the treatment
weight included baseline confounders, time-varying confounders
affected by exposure, and time as independent variables, while the
model for the treatment weight numerator included only time and
baseline confounders. The models for the censoring weight
numerator and denominator were identical to those for the treatment
weights, except that the censoring models also included time-varying
HAART as a predictor. Then, these IPTC weights were used in a
weighted pooled logistic model, which included baseline confounders,
to estimate the parameters of a Cox proportional hazards marginal
structural model [32,33]. Assuming no unmeasured confounding,
informative censoring, or model misspecification, weighting disasso-
ciates time-varying confounders with subsequent treatment and
censoring, effectively eliminating the causal intermediates complicat-
ing estimation of the effect of HAART on mortality. With the intent-
to-treat assumption that children starting HAART received it
uninterruptedly throughout follow-up—approximately true in our
program because adherence was checked at every visit and treatment
was never discontinued for active patients—the marginal structural
model yields a hazard ratio (HR) comparing the hazard of death had
all children initiated HAART to the hazard of death had no children
initiated HAART during follow-up.
For comparison, we also fit unadjusted as well as adjusted but
unweighted pooled logistic models. Additionally, to address
possible bias resulting from the dynamic visit schedule [34], we
utilized an alternative weighted model that employed the above
described IPTC weight multiplied by a visit attendance weight,
that is, an inverse probability of treatment, censoring, and visit
attendance (IPTCV) weight. The models for the probability of
having a visit were equivalent to the censoring weight models,
except that time since last visit was also included as a predictor.
The constancy of HRs over follow-up was assessed with models
that included an interaction term between HAART and
categorical time. Kaplan-Meier curves to visualize the impact of
HAART on survival were constructed; unstabilized weights were
used to obtain unconditional, unstratified IPTCV-weighted curves
[35]. The complements of Kaplan-Meier curves were plotted as
estimates of cumulative incidence. 95% confidence intervals (CIs)
for marginal structural model HRs were based on robust variance
to account for within-subject correlation induced by weighting.
Our pooled dataset included one row per person-day, with missing
covariate data carried forward from the last observation.
Confounders were selected based on a posited causal directed
acyclic graph [36] and previous studies. Baseline confounders were
WHO HIV clinical stage and severity of immunodeficiency, age,
and gender; time-varying confounders affected by prior exposure
were cotrimoxazole prophylaxis, HIV-related symptoms or
conditions, and CD4 cell percentage. HAART, gender, cotrimox-
azole, and symptoms or conditions were coded dichotomously.
HIV-related symptoms or conditions included one or more of the
following: Kaposi’s sarcoma, oral or esophageal candidiasis, severe
weight loss, tuberculosis, fever or diarrhea lasting 1 mo or more,
lymphocytic interstitial or Pneumocystis jirovecii pneumonia, chronic
herpes simplex, oral hairy leukoplakia, cryptococcal meningitis,
toxoplasma or HIV encephalopathy, or HIV-associated nephrop-
athy. Because it was generally assessed only at enrollment, clinical
stage was that at HIV care initiation for all children, including
those for whom follow-up began at first CD4 percentage result.
Severity of immunodeficiency was calculated according to WHO
guidelines [27] using CD4 and age at baseline. Both clinical stage
and severity of immunodeficiency were coded into four levels and
treated as indicator variables in multivariable analyses. CD4
percentage, age, and time were modeled as restricted cubic splines
with four knots, at the 5th, 35th, 65th, and 95th percentiles.
Results
Characteristics of the 790 children at baseline are shown in
Table 1. The median age was 5.9 y (interquartile range [IQR]
2.7–9.8), and roughly one-half were female (52.5%). The majority
of patients had severe immunodeficiency (57.2%), as reflected in
the low median CD4 percentage of 15 (IQR 9–22). Most children
had advanced HIV, as indicated by clinical stage 3 or 4 (51.3%),
and 19.9% had evidence of at least one HIV-related symptom or
condition.
The 790 children, 619 of whom initiated HAART (78.4%)
during follow-up, were followed for a median of 31.2 mo (IQR
10.3–53.6) and had a median of 30 HIV care visits (IQR 11–57).
Of those who started treatment, 110 (17.8%) switched to an
alternative regimen because of an adverse event or treatment
failure. At baseline, compared to those who remained untreated,
children who initiated HAART later had a greater degree of
immunodeficiency (p,0.01) with a corresponding lower median
CD4 percentage (p,0.01), had a more advanced HIV clinical
stage (p,0.01), and were more likely to have at least one HIV-
related symptom or condition (p,0.01). Those who initiated
HAART were similar to those who did not in terms of gender
(p = 0.05) and median age (p = 0.17), as well as cotrimoxazole
initiation at the beginning of follow-up (p = 0.05). The median
duration of observation for children who started HAART, 36.9
mo (IQR 14.0–55.7), with 31.3 of those months (IQR 11.4–52.0)
during receipt of HAART, was longer than the median 11.5 mo
(IQR 3.0–27.0) observed for untreated children (p,0.01), and
there was a parallel difference in median number of visits (40
versus 9, p,0.01).
Eighty children (10.1%) died during the 2,089.8 accrued
person-years of follow-up, an overall mortality rate of 3.8 deaths
per 100 person-years (95% CI 3.1–4.8). The unadjusted mortality
rate ratio comparing HAART to no HAART was 0.54 (95% CI
0.34–0.85). There were 51 deaths during the 1,620.9 person-years
(77.6% of total follow-up) contributed by children receiving
HAART, a rate of 3.2 deaths per 100 person-years (95% CI 2.4–
4.2), and 29 deaths during the 468.9 non-HAART person-years, a
rate of 6.0 deaths per 100 person-years (95% CI 4.1–8.6). The
mortality rates per 100 person-years during and after the first 90 d
of HAART were 16.4 (95% CI 11.0–24.5) and 1.8 (95% CI 1.3–
2.7), respectively. The proportion of HAART-untreated children
who died (17.0%) was higher than the 8.2% of HAART-initiating
children who died (p,0.01), and the absolute 3-y risk of death for
children receiving HAART was 0.14 compared with 0.48 for
children not receiving treatment. Thus, the unadjusted HAART
mortality risk ratio was 0.31 (95% CI 0.23–0.43). Six children
(0.8%) transferred to a different care provider, and 76 (9.6%) were
lost to follow-up. A smaller proportion of children who initiated
HAART (7.9%) than untreated children (19.3%) either transferred
to a different care provider or were lost to follow-up (p,0.01),
suggesting that HAART, with its associated more frequent visit
schedule, improved retention in care, and reflecting that children
who were in care for a shorter period of time had less opportunity
to begin treatment. Figure 1, in addition to showing the reduction
in population size over time due to death, transfer of care, or loss
to follow-up, illustrates the timing of HAART initiation. Of the
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619 children who initiated treatment, 325 (52.5%) did so during
the first 30 days of follow-up.
Estimates of the effect of HAART on mortality are presented in
Table 2. Because patients with advanced disease are most likely to
begin treatment, an unadjusted model that did not account for this
confounding by indication suggested no effect of HAART on
mortality, relative to no HAART (HR 1.38, 95% CI 0.84–2.27). An
unweighted model that adjusted for baseline confounders only (HR
0.73, 95% CI 0.41–1.31), as well as an unweighted model that
additionally but improperly adjusted for time-varying confounders
(HR 0.67, 95% CI 0.37–1.21), shifted the estimates in the direction
of the null but also failed to clearly suggest a protective effect of
HAART on survival. After appropriately accounting for time-
dependent confounders affected by exposure using marginal
structural models, HAART was strongly protective against
mortality. The HR from an IPTC-weighted model was 0.17 (95%
CI 0.05–0.64), while that from an IPTCV-weighted model was 0.25
(95% CI 0.06–0.95). The HR from an IPTCV-weighted model
before the median event time of 2.8 mo, 0.29 (95% CI 0.09–0.95),
was similar to the HR of 0.18 (95% CI 0.03–0.99) after the median
(interaction p = 0.32). Advanced and severe immunodeficiency at
baseline, compared to not significant immunodeficiency, were the
only baseline factors independently associated with mortality in an
IPTCV-weighted model (HR 3.16, 95% CI 1.18–8.47, and HR
5.08, 95% CI 1.49–17.39, respectively). IPTCV-weighted cumula-
tive incidence curves depict the survival benefit of HAART, not
evident in the unweighted curves that do not adjust for confounding
and selection bias (Figure 2).
Discussion
This study, which uniquely uses observational data to estimate the
effect of HAART on mortality in a pediatric population in a
resource-deprived setting, revealed that treatment markedly im-
proved the survival of HIV-infected children in Kinshasa, DRC.
Using a marginal structural model, we estimated that HAART
reduced the hazard (rate) of mortality during follow-up, relative to no
HAART, by 75% (HR 0.25, 95% CI 0.06–0.95). Although it was
less precise, our result was essentially identical in magnitude to the
HR of 0.24 (95% CI 0.11–0.51) from the only other study in children
[12] to use a method that could overcome barriers to unbiased effect
estimation in non-randomized data, such as time-dependent
Table 1. Characteristics of 790 HIV-infected children initiating HIV care in Kinshasa, DRC, between December 2004 and May 2010.
Time Period Characteristic Subcategory Total (n=790)
Initiated HAART
(n=619) No HAART (n=171) p-Valuea
Baselineb Median age, years (IQR) 5.9 (2.7–9.8) 5.9 (2.6–9.6) 5.9 (3.4–10.2) 0.17
Age, n (%) ,1 63 (8.0) 52 (8.4) 11 (6.4) 0.76
1–4 277 (35.1) 218 (35.2) 59 (34.5)
5–9 265 (33.5) 208 (33.6) 57 (33.3)
10–17 185 (23.4) 141 (22.8) 44 (25.7)
Female sex, n (%) 415 (52.5) 314 (50.7) 101 (59.1) 0.05
HIV clinical stage (WHO), n (%) 1 153 (19.4) 80 (12.9) 73 (42.7) ,0.01
2 232 (29.4) 176 (28.4) 56 (32.7)
3 369 (46.7) 331 (53.5) 38 (22.2)
4 36 (4.6) 32 (5.2) 4 (2.3)
Median CD4 percentage (IQR) 15 (9–22) 13 (7–20) 22 (16–28) ,0.01
Severity of immunodeficiency
(WHO), n (%)
Not significant 174 (22.0) 100 (16.2) 74 (43.3) ,0.01
Mild 88 (11.1) 56 (9.0) 32 (18.7)
Advanced 76 (9.6) 57 (9.2) 19 (11.1)
Severe 452 (57.2) 406 (65.6) 46 (26.9)
HIV symptoms or conditions,
n (%)
157 (19.9) 139 (22.5) 18 (10.5) ,0.01
Started cotrimoxazole at first
visit, n (%)
726 (91.9) 575 (92.9) 151 (88.3) 0.05
Follow-up Total person-years accrued 2,089.8 1,832.8 257.0 N/A
HAART person-years accrued 1,620.9 1,620.9 0.0 N/A
Median months of follow-up
(IQR)
31.2 (10.3–53.6) 36.9 (14.0–55.7) 11.5 (3.0–27.0) ,0.01
Median number of program
visits (IQR)
30 (11–57) 40 (16–61) 9 (4–18) ,0.01
Lost to follow-up or transferred
care, n (%)
82 (10.4) 49 (7.9) 33 (19.3) ,0.01
Died, n (%) 80 (10.1) 51 (8.2) 29 (17.0) ,0.01
ap-Values are for the comparison of children who received HAART to children who did not receive HAART.
bBaseline was date of first CD4 percentage result for 41 of 790 children (5.2%) for whom CD4 percentage at enrollment was not available. For these 41 children, the
median number of months from enrollment to first CD4 percentage was 2.3 (IQR 1.1–5.3).
doi:10.1371/journal.pmed.1001044.t001
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confounders affected by exposure. This is particularly noteworthy
since the earlier study included children enrolled in a multicenter
prospective cohort study in the United States. Combining the results
from the two studies in a mini meta-analysis by inverse variance
weighting, the HR was 0.24 with a 95% CI of 0.12–0.47.
The equivalence of these HRs offers evidence that HAART is as
effective in improving the survival of HIV-infected children in the
DRC, a severely resource-deprived nation still recovering from its
recent history of poor governance and civil wars [37], as it is in
resource-privileged settings. This result parallels the consistency of
effect observed between adults in Europe and the United States
[38] and South Africa [39], and is important because virtually all
children receiving HAART around the world, because of scale-up
of antiretroviral provision in low- and middle-income countries,
live in resource-poor areas [13]. Pediatric HIV programs in sub-
Saharan Africa, like ours in Kinshasa, often face challenges that
could adversely affect patient survival, including limited drug
options and diagnostic capacity, delayed healthcare seeking and
poor retention in care, and prevalent comorbidities and undernu-
trition [40]. These factors emphasize why a homogeneous effect of
HAART on survival in children could not be assumed across
different settings. Evidence of the interaction between HAART
and nutrition is limited, but it has been speculated that
micronutrient deficiencies may decrease the effectiveness of
antiretroviral drugs [41]. If true, this might have resulted in effect
estimates that were attenuated compared to the case where
children were better nourished overall, although it makes the
results applicable to similar populations. The higher mortality rate
observed during the first 90 d of HAART, compared to the rate
after 90 d of therapy, was consistent with findings in multiple prior
pediatric studies [21–25].
Figure 1. Number of active children by month of follow-up and HAART status. The timing of HAART initiation, in addition to the reduction
in population size over time due to death, transfer to a different care provider, or loss to follow-up, is illustrated.
doi:10.1371/journal.pmed.1001044.g001
Table 2. Estimated effect of HAART on mortality among 790
HIV-infected children initiating HIV care in Kinshasa, DRC,
between December 2004 and May 2010.
Model HR
Robust
95% CI
Unweighted, unadjusted (no confounders) 1.38 0.84–2.27
Unweighted, adjusted (baseline
confounders only)
0.73 0.41–1.31
Unweighted, adjusted (baseline and
time-varying confounders)
0.67 0.37–1.21
IPTC-weighted 0.17 0.05–0.64
IPTCV-weighted 0.25 0.06–0.95
All estimates are derived from pooled logistic models that include time
modeled as a restricted cubic spline with four knots. Comparing HAART to no
HAART, the unadjusted mortality rate ratio was 0.54 (95% CI 0.34–0.85), while
the unadjusted ratio of 3-y mortality risks was 0.31 (95% CI 0.23–0.43).
doi:10.1371/journal.pmed.1001044.t002
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The validity of results is contingent upon methodological
assumptions, one of which is the inclusion of all the important
confounders. Although HIV viral loads were infrequently assessed,
it is arguable that this factor, when available, was prognostic for
and affected by HAART, as well as associated with survival. While
not including viral load is a limitation that may have introduced
some bias into our estimates, failing to account for this factor may
have had only minimal effect. In the study by Patel et al. [12], the
HR of 0.30 (95% CI 0.11–0.82) in the 36% of children with HIV
RNA measurements was similar to the overall HR, which was not
adjusted for viral load: 0.24 (95% CI 0.11–0.51). Limited
availability of second- and third-line drug options, and being able
to measure virological suppression only occasionally, also meant
that some children who were recorded as receiving treatment
could have actually been failing therapy (i.e., their treatment was
not effective). This may have diluted the estimated effect of
HAART if these patients were more likely to die. However,
because children were frequently evaluated both clinically and
immunologically, and because adherence was routinely assessed, it
is expected that inadequate virological control was uncommon.
As suggested by several recent pediatric studies [21,24,42], it is
conceivable that some children classified as lost to follow-up had
died, which might have affected both the validity and precision of
our estimate. If this was more common amongst children not
receiving HAART, possibly because there was less opportunity to
discern deaths in these children owing to their less frequent clinic
visits, the strength of effect could have been underestimated.
Because children not receiving HAART had fewer appointments,
their data were correspondingly carried forward to a greater degree,
which also may have affected results. On a related note, covariate
data were quite complete. The variable most often missing, because
it required laboratory testing and not just simple collection onto
forms during clinic visits, was CD4 cell percentage. Assuming that
children were on average halfway to their next scheduled test when
follow-up concluded, 83% of the expected number of results were
available. Data on other time-varying factors were close to fully
complete. It is important to emphasize that the methods used will
not yield a fully unbiased measure unless all underlying assumptions
are met. If study imperfections occurred (e.g., misclassification of
HAART status, or the incorrect recording of HIV-related
symptoms or imprecise diagnosis of certain conditions such as
cryptococcal meningitis, which may have occurred due to the
limited capacity in Kinshasa), this is a possibility.
Strengths of our study included precise ascertainment of dates of
HAART initiation and death, regular patient follow-up, which
mitigated the influence of the carrying forward of data, and no
treatment discontinuation by any active patient, which allowed for
the intent-to-treat assumption and straightforward effect interpre-
tation. In our setting, patients who missed visits were actively
tracked, which decreased the possibility that children who died
were misclassified as lost to follow-up. This is supported by the fact
that during the first 90 d of HAART, a period when the rate of
mortality was high (16.4 per 100 person-years, 95% CI 11.0–24.5),
the rate of loss to follow-up was comparatively much lower (3.4 per
100 person-years, 95% CI 1.4–8.2). No child had ever received
therapy prior to participation in our program, which adds to the
generalizability and relevance of our results because most children
initiating HAART worldwide are treatment-naı¨ve. Furthermore,
given the brief history and limited availability of vertical
transmission prevention services in Kinshasa, it is unlikely that
many children had been previously exposed to prophylactic NVP.
This means that NVP-resistant HIV variants [43,44] were
probably rare, and increases the likelihood that the NVP-based
regimens most children received were effective. Patel et al. [12]
sensibly speculate that a stronger HR than 0.24 would have been
estimated had their population been naı¨ve to treatment rather
than experienced. If true, because our HR of 0.25 was comparable
despite arising from treatment-naı¨ve children, it is possible that the
aforementioned underlying contextual factors may have moved
our estimate modestly towards the null.
The large difference between the HRs from the unweighted and
weighted models indicates that there was considerable time-
dependent confounding, and validates the analytical approach.
The importance of accounting for dynamic visit schedules is
highlighted by the distinct HRs from the IPTC- and IPTCV-
weighted models.
In summary, HAART had a substantial beneficial impact on
the survival of HIV-infected children in Kinshasa, DRC. Along
with supplementing the limited knowledge base on the quantitative
effects of pediatric treatment, this study presents the first valid
estimate, to our knowledge, of the extent to which therapy
decreases mortality in a highly relevant population of HIV-
infected children living in a resource-deprived setting. Our
estimate, which represents the expected outcome had HAART
been evaluated via randomized assignment, provides compelling
evidence that the accelerating rollout of antiretrovirals could save
substantial numbers of lives. Pooled data from pediatric cohorts in
less developed areas should be used in future research not only to
generate more precise effect estimates, but also to focus on the
effects of HAART within particular groups such as undernour-
ished children, which remain incompletely understood.
Figure 2. Cumulative incidence curves depicting the effect of
HAART on survival among 790 HIV-infected children. In (A), the
curves are unweighted. In (B), the curves are weighted by the IPTCV.
doi:10.1371/journal.pmed.1001044.g002
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Editors’ Summary
Background. In 2009, an estimated 2.5 million children
were living with HIV, the majority of whom (2.3 million) were
in sub-Saharan Africa. Most (90%) of these children acquired
HIV from their HIV-infected mothers during pregnancy, birth,
or breastfeeding, highlighting the importance of giving
effective drugs for the prevention of mother to child
transmission. As such interventions are still not widely
accessible or available in most resource-limited countries,
where the burden of HIV is highest, every day an estimated
1,000 children were newly infected with HIV in 2009, but only
360,000 children were receiving highly active antiretroviral
therapy (HAART).
Although HAART improves the survival of adults living with
HIV, less is known about the degree to which HAART affects
the survival of HIV-infected children—although response to
antiretroviral treatment is known to differ across age groups.
Furthermore, as the course of HIV disease in children is
different from that in adults (partly because of the impact of
the virus on the immature thymus, which can lead to high
HIV RNA viremia and rapid death), it is inappropriate to
extrapolate results from studies of adults to pediatric
populations. Therefore, it is imperative that the effect of
HAART on survival be quantified specifically in children.
Why Was This Study Done? Most observational studies of
the effects of treatment on child survival have been
undertaken in high-income countries, such as Italy and the
United States. As most children with HIV live in low-resource
areas, where multiple factors, such as delayed presentation
to care and a higher incidence of co-occurring conditions,
might adversely affect treatment outcomes, there is a
specific need for information on the effects of HAART in
children with HIV living in low-income countries. Although
some investigations have taken place in pediatric cohorts
from such countries (for example, Coˆte d’Ivoire, Haiti,
Lesotho, Thailand, and Zambia), the effect of HAART on
mortality has not been accurately quantified among children
in a resource-deprived setting. Therefore, in this
observational clinical cohort study, the researchers
investigated the effect of HAART on mortality in HIV-
infected children in Kinshasa, in the Democratic Republic
of the Congo (DRC).
What Did the Researchers Do and Find? The researchers
analyzed data from 790 children enrolled into an HIV
program in Kinshasa, DRC, between December 2004 and
May 2010 and used a statistical model (marginal structural
models) to adjust for time-dependent confounding factors,
such as the fact that HAART is typically initiated in sicker
patients, for example, those with lower CD4 cell percentages.
Assuming that all children starting HAART received it
uninterruptedly throughout follow-up, using this statistical
model, the researchers were able to compare the hazard
ratio of death had all children initiated HAART to that had no
children initiated HAART during follow-up.
In the study, 619 out of the 790 children (78.4%) initiated
HAART during follow-up and were followed for a median of
31.2 months, with a median of 30 HIV care visits. Of those
who started treatment, 110 (17.8%) switched to an
alternative regimen because of an adverse event or
treatment failure. During the 2,089.8 accrued person-years
of follow-up, 80 children (10.1%) died, giving an overall
mortality rate of 3.8 deaths per 100 person-years. The
unadjusted mortality rate ratio comparing HAART to no
HAART was 0.54. Using a marginal structural model, the
researchers estimated that compared to no HAART, HAART
reduced the hazard (rate) of mortality during follow-up by
75%.
What Do These Findings Mean? These findings show
that treatment with HAART markedly improved the survival
of children infected with HIV in Kinshasa, DRC, and suggest
that HAART is as effective in improving the survival of HIV-
infected children in a severely resource-deprived country
(still recovering from civil war) as in more resource-privileged
settings—an important finding given that the vast majority
of children receiving HAART live in resource-poor areas. This
study provides additional evidence that accelerating rollout
of antiretroviral therapy to children with HIV in resource-
poor countries is lifesaving and effective. Future research
needs to address how effective HAART is in understudied
populations in resource-poor countries, such as
undernourished children or those with co-infections such
as tuberculosis.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001044.
N The World Health Organization’s Web site has more
information about the treatment of children living with HIV
N Me´decins Sans Frontie`res’s Campaign for Access to
Essential Medicines Web site has more information on
pediatric HAART
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